543 related articles for article (PubMed ID: 11510292)
1. Factors modulating cytosolic calcium. Role in lipid metabolism and cardiovascular morbidity and mortality in peritoneal dialysis patients.
Gadallah MF; el-Shahawy M; Andrews G; Ibrahim M; Ramdeen G; Hanna D; Gorospe W; Morkos A; Abbassian M; Moles K
Adv Perit Dial; 2001; 17():29-36. PubMed ID: 11510292
[TBL] [Abstract][Full Text] [Related]
2. Lipid Metabolism and Cardiovascular Morbidity and Mortality in Hemodialysis Patients: Role of Factors Modulating Cytosolic Calcium.
Gadallah MF; El-Shahawy M; Andrews G; Torres-Rivera C; Hanna D; Blatt M; Ibrahim M; Morkos A; Abbassian M; Cooper M
Hemodial Int; 2001 Jan; 5(1):59-65. PubMed ID: 28452450
[TBL] [Abstract][Full Text] [Related]
3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
4. Parathyroid hormone levels, calcium-channel blockers, and the dyslipidemia of nondiabetic hemodialysis patients.
Zanos S; Mitsopoulos E; Sakellariou G
Ren Fail; 2005; 27(2):163-9. PubMed ID: 15807180
[TBL] [Abstract][Full Text] [Related]
5. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).
Tentori F; Blayney MJ; Albert JM; Gillespie BW; Kerr PG; Bommer J; Young EW; Akizawa T; Akiba T; Pisoni RL; Robinson BM; Port FK
Am J Kidney Dis; 2008 Sep; 52(3):519-30. PubMed ID: 18514987
[TBL] [Abstract][Full Text] [Related]
6. Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients.
Burke SK; Dillon MA; Hemken DE; Rezabek MS; Balwit JM
Adv Ren Replace Ther; 2003 Apr; 10(2):133-45. PubMed ID: 12879374
[TBL] [Abstract][Full Text] [Related]
7. Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study.
Naves-Díaz M; Passlick-Deetjen J; Guinsburg A; Marelli C; Fernández-Martín JL; Rodríguez-Puyol D; Cannata-Andía JB
Nephrol Dial Transplant; 2011 Jun; 26(6):1938-47. PubMed ID: 20513773
[TBL] [Abstract][Full Text] [Related]
8. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.
Block GA; Klassen PS; Lazarus JM; Ofsthun N; Lowrie EG; Chertow GM
J Am Soc Nephrol; 2004 Aug; 15(8):2208-18. PubMed ID: 15284307
[TBL] [Abstract][Full Text] [Related]
9. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
[TBL] [Abstract][Full Text] [Related]
10. Leptin as a marker of nutrition and cardiovascular risk in peritoneal dialysis patients.
Aguilera A; Bajo MA; Rebollo F; Díez JJ; Díaz C; Paiva A; Codoceo R; Selgas R
Adv Perit Dial; 2002; 18():212-7. PubMed ID: 12402621
[TBL] [Abstract][Full Text] [Related]
11. Parathyroidectomy as a therapeutic tool for targeting the recommended NKF-K/DOQI ranges for serum calcium, phosphate and parathyroid hormone in dialysis patients.
Mazzaferro S; Pasquali M; Farcomeni A; Vestri AR; Filippini A; Romani AM; Barresi G; Pugliese F
Nephrol Dial Transplant; 2008 Jul; 23(7):2319-23. PubMed ID: 18281320
[TBL] [Abstract][Full Text] [Related]
12. Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis.
Nasri H; Baradaran A; Naderi AS
Acta Med Austriaca; 2004 Aug; 31(3):67-72. PubMed ID: 15515479
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for vascular complications in patients on peritoneal dialysis.
Arima H; Nakamoto H; Okada S; Inoue T; Kobayashi K; Shoda J; Ikeda N; Kanno Y; Sugahara S; Okada H; Suzuki H
Adv Perit Dial; 2006; 22():192-7. PubMed ID: 16983968
[TBL] [Abstract][Full Text] [Related]
14. Mineral metabolism and cardiovascular morbidity and mortality risk: peritoneal dialysis patients compared with haemodialysis patients.
Noordzij M; Korevaar JC; Bos WJ; Boeschoten EW; Dekker FW; Bossuyt PM; Krediet RT
Nephrol Dial Transplant; 2006 Sep; 21(9):2513-20. PubMed ID: 16799173
[TBL] [Abstract][Full Text] [Related]
15. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study.
Slinin Y; Foley RN; Collins AJ
J Am Soc Nephrol; 2005 Jun; 16(6):1788-93. PubMed ID: 15814832
[TBL] [Abstract][Full Text] [Related]
16. PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis.
Danese MD; Kim J; Doan QV; Dylan M; Griffiths R; Chertow GM
Am J Kidney Dis; 2006 Jan; 47(1):149-56. PubMed ID: 16377396
[TBL] [Abstract][Full Text] [Related]
17. Cardiac troponin I in patients with chronic kidney disease treated conservatively or undergoing long-term haemodialysis.
Flisiński M; Strózecki P; Stefańska A; Zarzycka-Lindner G; Brymora A; Manitius J
Kardiol Pol; 2007 Sep; 65(9):1068-75; discussion 1076-8. PubMed ID: 17975754
[TBL] [Abstract][Full Text] [Related]
18. Polyglucose dialysis solution induces changes in blood chemistry.
Grzegorzewska AE; Antczak-Jedrzejczak D; Leander M; Mariak I
Adv Perit Dial; 2001; 17():101-8. PubMed ID: 11510254
[TBL] [Abstract][Full Text] [Related]
19. The association of lipid levels with mortality in patients on chronic peritoneal dialysis.
Habib AN; Baird BC; Leypoldt JK; Cheung AK; Goldfarb-Rumyantzev AS
Nephrol Dial Transplant; 2006 Oct; 21(10):2881-92. PubMed ID: 16735386
[TBL] [Abstract][Full Text] [Related]
20. Oral vitamin D supplementation reduces the incidence of eucalcemic PTH elevation after surgery for primary hyperparathyroidism.
Beyer TD; Solorzano CC; Prinz RA; Babu A; Nilubol N; Patel S
Surgery; 2007 Jun; 141(6):777-83. PubMed ID: 17560254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
